Immutep
Search :
Corporate Information
Product Development
Clinical Trials
Business Strategy
Investor Relations
Contact Us
News
September 9, 2010
Topics:
Corporate Information
Product Development
Clinical Trials
Business Strategy
Investor Relations
Contact Us
Visit Us
Subway Map
Car Map
Intranet
News
On this page:
>
Présentation
>
Page bottom
Home
»
Contact Us
»
Visit Us
Immutep S.A.
Faculté de Pharmacie, 5 rue Jean-Baptiste Clément, 92296 Châtenay-Malabry, FRANCE.
© 2002 Immutep, S.A.
Press Release
05/2010 -
Immutep Announces Oral Presentation at ASCO Annual Meeting of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
Immutep S.A. announced today that the final results from its Phase ...
01/2010 -
ImmuFact IMP321 doubles clinical response rate in first-line metastatic breast cancer
Immutep S.A. announced today the final results from its Phase I/II ...
10/2009 -
New results confirm that ImmuFact IMP321 doubles clinical response rate
Immutep S.A. announced today interim results from the first three ...
09/2009 -
Clinical research paper describes IMP321’s potency in inducing progression-free survival improvement and effector memory T cells
Immutep S.A. announced today the publication of a clinical research ...
04/2009 -
A Phase I clinical trial of ImmuFact IMP321 in pancreatic cancer has started at Washington University in Saint Louis (MO)
Immutep S.A. announced today the first administration of IMP321 in ...